Pictet Asset Management Holding SA Has $127.19 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Pictet Asset Management Holding SA lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,046,025 shares of the biotechnology company’s stock after selling 4,986 shares during the period. Pictet Asset Management Holding SA owned 1.10% of Sarepta Therapeutics worth $127,186,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $126,315,000. Wellington Management Group LLP boosted its holdings in shares of Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after buying an additional 665,087 shares during the period. Erste Asset Management GmbH bought a new position in Sarepta Therapeutics in the 3rd quarter worth $79,425,000. Janus Henderson Group PLC raised its holdings in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares during the period. Finally, Soros Fund Management LLC bought a new stake in Sarepta Therapeutics during the third quarter valued at about $25,800,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 1.9 %

Shares of SRPT opened at $70.41 on Friday. The business’s 50 day simple moving average is $102.66 and its 200-day simple moving average is $116.06. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a one year low of $69.81 and a one year high of $173.25. The company has a market capitalization of $6.83 billion, a P/E ratio of 56.33 and a beta of 0.79.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SRPT. Cantor Fitzgerald reissued an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft cut their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a report on Wednesday, March 19th. Scotiabank lowered their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. HC Wainwright reissued a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, March 19th. Finally, Royal Bank of Canada dropped their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $167.41.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.